MED21

MED21 (SRB7/SURB7) is an essential subunit of the Mediator complex that physically couples Mediator to RNA polymerase II and is required for transcriptional regulation by this complex (PMID:8598913, PMID:9671713). It co-purifies exclusively with high-molecular-weight Pol II holoenzyme forms containing TFIIE and TFIIH and confers heightened responsiveness to transcriptional activators (PMID:8598913), and orthologous Mediator complexes containing MED21 bind the Pol II CTD and stimulate its phosphorylation by TFIIH (PMID:9671713). MED21 resides in complexes with dual regulatory output, capable of both repressing and synergistically enhancing activator-dependent transcription depending on TFIIH availability (PMID:9734358, PMID:10024883). Structurally, MED21 forms an extended, hinged heterodimer with MED7 comprising a four-helix bundle and a coiled-coil protrusion, presenting protein-binding surfaces that nucleate assembly of the Mediator middle module and engage MED6 to bridge toward the head module (PMID:15710619); within yeast Mediator the MED7·MED21 heterodimer forms a central tetramer with Med4/Med9 flanked by Med10 and Med31 (PMID:23939621). MED21 directly contacts MED7, MED10, MED6 and the co-repressor Tup1, with interactions critically dependent on its N-terminal residues 2–8 (PMID:16758199), and the integrity of the MED7-MED21 flexible hinge is required for Mediator to bind Pol II and form the holoenzyme (PMID:27821593). Beyond holoenzyme assembly, MED21 acts after initiation: yeast med21 mutations impair Pol II transit and processivity through coding regions and nucleosome displacement without blocking Pol II recruitment (PMID:22377631). MED21 is single-copy, ubiquitously expressed, and essential for cell viability and embryonic development (PMID:10500093), and it is required for epidermal differentiation (PMID:20520624) and HIV-1 transcription (PMID:25100719).

1. 1996 High

   Established that human SRB7/MED21 is a bona fide component of a mammalian Pol II holoenzyme, extending the yeast Mediator paradigm to human transcription and tying MED21 to activator-responsive transcription.

   Evidence Antibody-based purification and in vitro transcription assays of a holoenzyme containing TFIIE/TFIIH

   PMID:8598913

   Open questions at the time

   • Did not resolve MED21's position or direct contacts within the complex
   • Mechanism of enhanced activator responsiveness not defined
2. 1998 High

   Showed that MED21-containing Mediator engages the Pol II CTD and stimulates its phosphorylation by TFIIH, linking MED21 complexes to CTD-dependent regulation, while a distinct NAT complex repressed transcription and phosphorylated the CTD at sites distinct from TFIIH.

   Evidence Protein purification with CTD binding and phosphorylation assays; biochemical purification with in vitro repression and kinase assays

   PMID:9671713 PMID:9734358

   Open questions at the time

   • MED21's specific contribution to CTD binding versus other subunits unclear
   • Relationship between the activating and repressive complexes not resolved
3. 1999 Medium

   Defined the dual, context-dependent output of MED21-containing complexes, showing the SMCC/Mediator can either repress or synergistically enhance activator-dependent transcription depending on TFIIH levels.

   Evidence Biochemical purification with in vitro transcription and activator-interaction assays; reciprocal co-IP with hTRFP and Pol II

   PMID:10024883 PMID:9933582

   Open questions at the time

   • Molecular switch controlling repression versus activation not defined
   • MED21's direct role in these opposing activities not isolated
4. 1999 High

   Demonstrated that MED21 is single-copy, ubiquitously expressed, and essential, establishing it as required for cell viability and embryonic development.

   Evidence Northern blot, ES cell gene knockout, and co-fractionation in mouse

   PMID:10500093

   Open questions at the time

   • Did not distinguish whether lethality reflects loss of Mediator integrity versus a MED21-specific function
   • Cell-type-specific requirements not addressed
5. 2000 Medium

   Tested whether MED21 alone can drive transcription when recruited to a promoter, showing that direct recruitment is insufficient for activation despite holoenzyme association.

   Evidence Fusion-protein recruitment and reporter assays in mammalian cells

   PMID:10825198

   Open questions at the time

   • Does not exclude activation in other promoter or cellular contexts
   • Negative result; mechanism of why recruitment fails not defined
6. 2002 Medium

   Revealed a functional interaction between MED21 and the CDK8 (Srb8/10/11/Sin4) module, showing that lexA-Srb7 acts as a cryptic activator unmasked when the repressive module is absent.

   Evidence lexA-fusion reporter assays with genetic dependencies and co-IP in yeast

   PMID:12468546

   Open questions at the time

   • Direct physical link between MED21 and CDK8 module not established
   • Whether cryptic activation reflects a native regulatory mechanism unclear
7. 2005 High

   Provided the atomic-resolution architecture of the MED7·MED21 heterodimer, defining an extended hinged structure with protein-binding surfaces for middle-module assembly and MED6 bridging to the head module.

   Evidence 3.0 Å X-ray crystallography with structure-function analysis

   PMID:15710619

   Open questions at the time

   • Functional role of the flexible hinge not yet tested
   • Structure of the full middle module within intact Mediator not resolved
8. 2006 High

   Mapped MED21's direct interaction network and the residues that drive it, identifying contacts with MED7, MED10, MED6 and Tup1 and showing dependence on N-terminal residues 2–8.

   Evidence Yeast two-hybrid, co-IP of tagged proteins in heterologous systems, and high-copy suppressor screen of a med21-ts mutant

   PMID:16758199

   Open questions at the time

   • Functional consequence of the Tup1 contact not defined
   • Whether all interactions occur simultaneously within assembled Mediator unclear
9. 2012 High

   Uncovered a post-initiation function for MED21, showing mutations impair Pol II transit, processivity, and nucleosome displacement through coding regions without affecting Pol II recruitment.

   Evidence Genetic mutation analysis with ChIP, 6-azauracil sensitivity, and reporter assays in yeast

   PMID:22377631

   Open questions at the time

   • Molecular mechanism linking MED21 to elongation/nucleosome dynamics not defined
   • Whether this elongation role is conserved in mammals not tested here
10. 2013 Medium

    Placed the MED7/MED21 heterodimer within the topology of the middle module, defining its position in a central tetramer with Med4/Med9 flanked by Med10 and Med31.

    Evidence Lysine cross-linking mass spectrometry with 3D modeling in yeast

    PMID:23939621

    Open questions at the time

    • Model derived from cross-linking, not independently validated by high-resolution structure
    • Conformational dynamics within intact Mediator not captured
11. 2016 High

    Established the functional importance of the MED7-MED21 hinge, showing hinge integrity is required for Mediator-Pol II binding and holoenzyme formation.

    Evidence Point mutagenesis with Mediator-Pol II binding assays and negative-stain EM on human Mediator

    PMID:27821593

    Open questions at the time

    • Precise conformational change at the hinge during Pol II engagement not resolved
    • How hinge flexibility is regulated in vivo unknown
12. 2014 Medium

    Identified MED21 as a host factor co-opted for pathogen transcription, showing its knockdown impairs HIV-1 replication at a post-integration transcriptional step.

    Evidence siRNA knockdown with viral replication and HIV transcript assays in human cells

    PMID:25100719

    Open questions at the time

    • Whether MED21 acts directly at the HIV promoter or via general Mediator function unclear
    • Mechanistic link to Tat/HIV transcription machinery not defined
13. 2010 Medium

    Demonstrated a tissue-specific developmental requirement, showing MED21 knockdown causes keratinocyte hyperproliferation and blocks calcium-induced differentiation.

    Evidence siRNA knockdown, VDR affinity purification, RT-PCR and immunofluorescence in human keratinocytes

    PMID:20520624

    Open questions at the time

    • Direct target genes through which MED21 controls differentiation not identified
    • Whether phenotype reflects MED21-specific versus general Mediator loss unclear

• How the conformational flexibility of the MED7-MED21 hinge is regulated to control Pol II engagement, and how MED21's middle-module function is coupled to elongation and gene-specific regulation in mammalian cells, remain unresolved.
• No mechanism connecting MED21 to elongation defined at molecular resolution in mammals
• Regulatory inputs controlling hinge conformation unknown
• Direct gene targets of MED21-dependent regulation in differentiation not mapped